LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Aandelen Lijst・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Gesloten

4.05 -0.98

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

4.01

Max

4.09

Belangrijke statistieken
By Trading Economics
Inkomsten	-8.5M -35M
Werknemers	106
EBITDA	-11M -37M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+72.84% upside

Dividenden
By Dow Jones
Volgende Winsten	19 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	131M 295M
Vorige openingsprijs	5.03
Vorige sluitingsprijs	4.05

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

1.23 / 1.45 Steun & Weerstand

Zentalis Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 mei 2026, 23:53 UTC

Acquisities, Fusies, Overnames

Prudential PLC to Buy Majority Stake in India Life Insurer for $389 Million

15 mei 2026, 22:47 UTC

Populaire aandelen

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 mei 2026, 22:16 UTC

Acquisities, Fusies, Overnames

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 mei 2026, 22:00 UTC

Belangrijke Marktbewegers

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 mei 2026, 18:09 UTC

Belangrijke Marktbewegers

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

17 mei 2026, 23:50 UTC

Marktinformatie

Gold Consolidates; May be Weighed by Fed Rate-Hike Expectations -- Market Talk

17 mei 2026, 23:43 UTC

Marktinformatie

Global Equities Roundup: Market Talk

17 mei 2026, 23:43 UTC

Marktinformatie

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

17 mei 2026, 23:36 UTC

Marktinformatie

Oil Rises Amid Prospects of Prolonged Strait of Hormuz Closure -- Market Talk

17 mei 2026, 23:07 UTC

Acquisities, Fusies, Overnames

UOB: Transactions Part of Group's Capital Reallocation Strategy

17 mei 2026, 23:06 UTC

Acquisities, Fusies, Overnames

UOB: Share Sale Agreements Entered With Singland Properties

17 mei 2026, 23:05 UTC

Acquisities, Fusies, Overnames

UOB: Divestments' Aggregate Consideration of S$299M in Cash

17 mei 2026, 22:31 UTC

Acquisities, Fusies, Overnames

Prudential PLC to Fund Stake Acquisition via Internal Resources

17 mei 2026, 22:31 UTC

Acquisities, Fusies, Overnames

Prudential PLC to Acquire Stake for $389 Million

17 mei 2026, 22:30 UTC

Acquisities, Fusies, Overnames

Prudential PLC to Acquire 75% Stake in Bharti Life Insurance

16 mei 2026, 16:27 UTC

Acquisities, Fusies, Overnames

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16 mei 2026, 15:26 UTC

Acquisities, Fusies, Overnames

NextEra Energy Near Deal for Rival Utility Dominion -- WSJ

16 mei 2026, 08:20 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

15 mei 2026, 22:17 UTC

Acquisities, Fusies, Overnames

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mei 2026, 21:59 UTC

Acquisities, Fusies, Overnames

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 mei 2026, 21:50 UTC

Acquisities, Fusies, Overnames

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mei 2026, 21:30 UTC

Acquisities, Fusies, Overnames

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 mei 2026, 21:16 UTC

Marktinformatie

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 mei 2026, 20:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

15 mei 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

15 mei 2026, 20:19 UTC

Populaire aandelen

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 mei 2026, 19:41 UTC

Acquisities, Fusies, Overnames

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 mei 2026, 19:35 UTC

Marktinformatie

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 mei 2026, 19:33 UTC

Marktinformatie

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 mei 2026, 18:35 UTC

Winsten

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

Peer Vergelijking

Prijswijziging

Zentalis Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

72.84% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 7 USD 72.84%

Hoogste 10 USD

Laagste 4 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Zentalis Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

7 ratings

Buy

Hold

Sell

Gebaseerd op 7 analisten die aandelenratings hebben gegeven aan Zentalis Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

1.23 / 1.45Steun & Weerstand

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

There is one bearish event.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.